1020264-43-0
Chemical Structure
SYN1327
- CAS No.: 1020264-43-0
- Formula:C72H101N19O16S2
- Molecular Weight:1552.82
InChIKey: OOEOTYYQESNHNZ-ZTYWXYLJSA-N
SMILES: O=C(N[C@@H](CCCNC(N)=N)C(N[C@@H](CC1=CC=CC=C1)C(N[C@@H](C(C)(SSC[C@@H](C(N)=O)NC2=O)C)C(N[C@@H]([C@H](O)C)C(NCC(N[C@@H](CC3=CNC=N3)C(N[C@@H](CC4=CC=CC=C4)C(NCC(N(C)CC(N(C)[C@@H](CC(C)C)C(N[C@@H](CC5=CC=C(C=C5)O)C(N6[C@H]2CCC6)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)C
Biological Activity: SYN1327 is a potent monomeric cyclic competitive antagonistic peptide targeting the neonatal Fc receptor (FcRn), with a Kd of 31 nM for human FcRn at pH 6 and a Kd of 170 nM at pH 7.4. SYN1327 competitively binds to the IgG-binding site of FcRn and inhibits the binding of human IgG to FcRn. SYN1327 acts as the monomeric precursor of the dimeric peptide SYN1436 (HY-P11882). SYN1327 can be used in studies related to IgG-mediated autoimmune diseases[1][2][3].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
SYN1327 | 99.75% | SYN1327 is a potent monomeric cyclic competitive antagonistic peptide targeting the neonatal Fc receptor (FcRn), with a Kd of 31 nM for human FcRn at pH 6 and a Kd of 170 nM at pH 7.4. SYN1327 competitively binds to the IgG-binding site of FcRn and inhibits the binding of human IgG to FcRn. SYN1327 acts as the monomeric precursor of the dimeric peptide SYN1436 (HY-P11882). SYN1327 can be used in studies related to IgG-mediated autoimmune diseases. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
-
[1]. Song X N, et al. The effect of pH and ligand density on the endocytosis and exocytosis process of FcBP decorated PEG‑PCL micelles on Caco‑2 cells[J]. Acta Pharmaceutica Sinica, 2017, 52(8): 1331‑1336.
- [2]. Mezo AR, et al. Reduction of IgG in nonhuman primates by a peptide antagonist of the neonatal Fc receptor FcRn. Proceedings of the National Academy of Sciences of the United States of America. 2008 Feb 19;105(7):2337-42. [Content Brief]
- [3]. McDonnell KA, et al. Synthesis and structure-activity relationships of dimeric peptide antagonists of the human immunoglobulin G-human neonatal Fc receptor (IgG-FcRn) interaction. Journal of medicinal chemistry. 2010 Feb 25;53(4):1587-96.
